Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 27, 2022

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic HNSCC

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
J. Clin. Oncol 2022 Oct 11;[EPub Ahead of Print], KJ Harrington, B Burtness, R Greil, D Soulières, M Tahara, G de Castro, A Psyrri, I Brana, N Basté, P Neupane, Å Bratland, T Fuereder, BGM Hughes, R Mesia, N Ngamphaiboon, T Rordorf, WZ Wan Ishak, J Lin, B Gumuscu, RF Swaby, D Rischin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading